February 22, 2022
ICER has announced its intent to issue a final evidence report in this review without first holding a public hearing, a highly unusual decision.
October 15, 2021
ICER’s priorities differ from severe asthma patients’, and the economists’ approach could make it harder for patients to access the…
October 12, 2021
Just as asthma impacts people differently, existing treatment options serve some patients better than others.
June 3, 2021
Alzheimer’s and dementia already afflict too many people, yet their prevalence is expected to more than double in the coming…
May 28, 2021
The Institute for Clinical and Economic Review claims that the first disease-modifying treatment for Alzheimer’s disease isn’t worth its cost.
April 30, 2021
An efficacious treatment that reduces the symptoms and risk factors associated with obstructive hypertrophic cardiomyopathy delivers great value to patients.…
December 10, 2020
The Institute for Clinical and Economic Review claims that new medications for high cholesterol aren’t worth their cost. The economists…
December 10, 2020
Effective treatments that reduce the risk factors associated with ASCVD offers tremendous value to the patient community. Read the Letter
March 18, 2020
The Institute for Clinical and Economic Review wants to assess the cost-effectiveness of breakthrough drugs for cystic fibrosis. But their…
March 16, 2020
Cystic fibrosis is a devastating disease that severely restricts patients’ quality of life and is associated with a shorter lifespan.…
